论文部分内容阅读
目的:探讨血塞通和尼莫地平注射液治疗脑梗死的经济可行性。方法:选择我院从2012年1月~2014年4月收治的132例脑梗死患者,随机分为观察组和对照组,各48例。两组均给予,在此基础上,对照组给予治疗,观察组治疗。结果:观察组和对照组各66例,观察组总有效率为81.82%,对照组为83.33%,两者无明显差异(P>0.05)。观察组和对照组平均每个患者花费3003元和3219元;观察组成本-效果的比值为36.70,对照组为38.63,观察组优于对照组。结论:脑梗死患者治疗中,采用血塞通注射液有更好的经济价值。
Objective: To explore the economic feasibility of Xuesaitong and Nimodipine injection in treating cerebral infarction. Methods: A total of 132 patients with cerebral infarction who were admitted to our hospital from January 2012 to April 2014 were randomly divided into observation group and control group, with 48 cases in each group. Both groups were given, on this basis, the control group given treatment, observation group treatment. Results: The observation group and the control group each 66 cases, the observation group the total effective rate was 81.82%, the control group was 83.33%, no significant difference between the two (P> 0.05). In the observation group and the control group, the average cost per patient was 3003 yuan and 3219 yuan; the ratio of the cost-effectiveness of the observation group was 36.70 and that of the control group was 38.63, and the observation group was superior to the control group. Conclusion: The treatment of patients with cerebral infarction, the use of Xuesaitong injection has better economic value.